ARWR Arrowhead Pharmaceuticals Inc.

67.27
+1.74  (+3%)
Previous Close 65.53
Open 66.43
Price To Book 26.28
Market Cap 6,438,278,976
Shares 95,708,027
Volume 1,984,983
Short Ratio
Av. Daily Volume 1,944,530
Stock charts supplied by TradingView

NewsSee all news

  1. Arrowhead Pharmaceuticals Closes Underwritten Public Offering with Gross Proceeds of $266.8 Million

    Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) today announced that on December 6, 2019 it closed the previously announced underwritten public offering of 4,600,000 shares of its common stock, which included shares issued

  2. Arrowhead Pharmaceuticals Announces Pricing of Underwritten Public Offering of Common Stock

    Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) today announced the pricing of an underwritten public offering of 4,000,000 shares of its common stock, offered at a price of $58.00 per share, before underwriting discounts.

  3. Arrowhead Pharmaceuticals Announces Proposed Underwritten Offering of Common Stock

    Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) today announced its intention to offer and sell 4,000,000 shares of its common stock in an underwritten offering pursuant to its existing automatic shelf registration

  4. Arrowhead Pharmaceuticals to Participate in Upcoming December 2019 Conferences

    Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) today announced that it is scheduled to participate in the following upcoming events: Piper Jaffray 31st Annual Healthcare Conference – New York, December 3-5,

  5. Arrowhead Pharmaceuticals Reports Fiscal Year 2019 Results

    - Conference Call and Webcast Today at 4:30 p.m. EST Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) today announced financial results for its fiscal year ended September 30, 2019. The company is hosting a conference call

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Announced that development will be discontinued - November 29, 2016.
ARC-AAT
Alpha-1 antitrypsin deficiency (AATD)
Announced that development will be discontinued - November 29, 2016.
ARC-521
Chronic Hepititis B (HBV)
Announced that development will be discontinued - November 29, 2016.
ARC-520 injection in combination with entecavir or tenofovir
Chronic Hepititis B (HBV)
Phase 2b initiation announced August 28, 2019.
ARO-HBV / JNJ-3989
Hepatitis B (HBV)
Phase 2/3 dosing has commenced - noted August 8, 2019.
ARO-AAT
Alpha-1 Liver Disease
Phase 1 initial data presented September 16, 2019 mean maximal reductions of plasma triglycerides of 66%.
ARO-ANG3
Dyslipidemia
Phase 1 initial data presented September 16, 2019 noted mean maximal reductions of plasma triglycerides of 63%.
AROAPOC31001
Familial chylomicronemia syndrome (FCS) / Hypertriglyceridemia
Phase 2 open label trial initiated 3Q 2019.
AROAAT2002 - Europe
AATD-associated liver disease

Latest News

  1. Arrowhead Pharmaceuticals Closes Underwritten Public Offering with Gross Proceeds of $266.8 Million

    Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) today announced that on December 6, 2019 it closed the previously announced underwritten public offering of 4,600,000 shares of its common stock, which included shares issued

  2. Arrowhead Pharmaceuticals Announces Pricing of Underwritten Public Offering of Common Stock

    Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) today announced the pricing of an underwritten public offering of 4,000,000 shares of its common stock, offered at a price of $58.00 per share, before underwriting discounts.

  3. Arrowhead Pharmaceuticals Announces Proposed Underwritten Offering of Common Stock

    Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) today announced its intention to offer and sell 4,000,000 shares of its common stock in an underwritten offering pursuant to its existing automatic shelf registration

  4. Arrowhead Pharmaceuticals to Participate in Upcoming December 2019 Conferences

    Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) today announced that it is scheduled to participate in the following upcoming events: Piper Jaffray 31st Annual Healthcare Conference – New York, December 3-5,

  5. Arrowhead Pharmaceuticals Reports Fiscal Year 2019 Results

    - Conference Call and Webcast Today at 4:30 p.m. EST Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) today announced financial results for its fiscal year ended September 30, 2019. The company is hosting a conference call

  6. Arrowhead Presents New Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3 at AHA Scientific Sessions 2019

    - Company Expects to Initiate Phase 3 Clinical Trials Next Year Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) today presented updated Phase 1 clinical data on its two RNAi-based cardiometabolic candidates, ARO-APOC3

  7. Arrowhead Pharmaceuticals Announces Planned Management Transition

    Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that Bruce Given, M.D., Arrowhead's chief operating officer and head of R&D, plans to retire on May 1, 2020, after a more than 30 year career in

  8. Arrowhead Pharmaceuticals to Webcast Fiscal 2019 Year End Results

    Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) today announced that it will host a webcast and conference call on November 25, 2019, at 4:30 p.m. EST to discuss its financial results for the fiscal year ended September

  9. Arrowhead and Collaborator Janssen Present Phase 2 Clinical Data for Investigational Hepatitis B Regimens at The Liver Meeting® 2019

    Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) today announced Phase 2 clinical data on a double combination of JNJ-3989 (formerly ARO-HBV) and a nucleos(t)ide analog (NA), and the first clinical data on a triple

  10. Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ENaC at the North American Cystic Fibrosis Conference

    Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) today presented preclinical data at the 2019 North American Cystic Fibrosis Conference (NACFC) on ARO-ENaC, an inhaled RNAi therapeutic being developed as a potential

  11. Arrowhead Pharmaceuticals Hosts R&D Day on Emerging Pipeline of RNAi Therapeutics

    Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is hosting a Research & Development (R&D) Day today in New York to discuss its emerging pipeline of RNAi therapeutics that leverage its proprietary Targeted RNAi

  12. Arrowhead Pharmaceuticals to Host R&D Day on Emerging Pipeline of RNAi Therapeutics

    Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) today announced that it will host a Research & Development (R&D) Day to discuss its emerging pipeline of RNAi therapeutics that leverage its proprietary Targeted RNAi

  13. Arrowhead Pharmaceuticals to Participate in Upcoming October 2019 Conferences

    Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) today announced that it is scheduled to participate in the following upcoming events: 2019 Cantor Global Healthcare Conference – New York, October 2-4, 2019 October 4,

  14. Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)

    Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) today announced that as an inducement to entering into employment with the Company, on September 13, 2019, the Compensation Committee of the Board of Directors approved

  15. Arrowhead Pharmaceuticals Presents Initial Top-Line Clinical Data and Preclinical Data on RNAi Candidates ARO-APOC3 and ARO-ANG3

    Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) today presented initial top-line clinical data at The Global Summit on Cardiology and Heart Diseases, being held in Dubai, UAE. The data demonstrate that, in two Phase I

  16. Arrowhead Pharmaceuticals to Participate in Upcoming September 2019 Conferences

    Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) today announced that it is scheduled to participate in the following upcoming events: Baird's 2019 Global Healthcare Conference – New York, September 4-5,

  17. Arrowhead Collaborator Janssen Begins REEF-1 Phase 2b Combination Study in Patients with Chronic Hepatitis B Infection

    - Arrowhead earns $25 million milestone payment in connection with trial initiation Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) today announced that Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical